Nutanix Announces Updates to its Board of Directors
Nutanix (NTNX) announced changes to its board of directors effective May 15, 2025. Eric K. Brandt, a seasoned executive with over 30 years of global experience, joins the board bringing extensive leadership and finance expertise. Brandt previously served as CFO of Broadcom Corporation until 2016 and held executive positions including CEO of Avanir Pharmaceuticals and CFO of Allergan. He currently serves on multiple corporate boards including Gen Digital, Lam Research, and Option Care Health.
Simultaneously, David Humphrey, a Partner at Bain Capital who joined the board following their $750 million investment in September 2020, has resigned. Max de Groen, another Bain Capital Partner, will continue serving on Nutanix's board. Bain Capital remains a significant stockholder in the company.
Nutanix (NTNX) ha annunciato cambiamenti nel suo consiglio di amministrazione a partire dal 15 maggio 2025. Eric K. Brandt, un dirigente con oltre 30 anni di esperienza globale, entra nel consiglio portando una vasta competenza in leadership e finanza. Brandt è stato CFO di Broadcom Corporation fino al 2016 e ha ricoperto ruoli esecutivi come CEO di Avanir Pharmaceuticals e CFO di Allergan. Attualmente siede in diversi consigli di amministrazione, tra cui Gen Digital, Lam Research e Option Care Health.
Contemporaneamente, David Humphrey, Partner di Bain Capital che era entrato nel consiglio dopo l'investimento di 750 milioni di dollari nel settembre 2020, si è dimesso. Max de Groen, altro Partner di Bain Capital, continuerà a far parte del consiglio di Nutanix. Bain Capital rimane un azionista importante della società.
Nutanix (NTNX) anunció cambios en su junta directiva con efecto a partir del 15 de mayo de 2025. Eric K. Brandt, un ejecutivo con más de 30 años de experiencia global, se une a la junta aportando amplia experiencia en liderazgo y finanzas. Brandt fue CFO de Broadcom Corporation hasta 2016 y ocupó cargos ejecutivos como CEO de Avanir Pharmaceuticals y CFO de Allergan. Actualmente forma parte de varios consejos corporativos, incluyendo Gen Digital, Lam Research y Option Care Health.
Al mismo tiempo, David Humphrey, socio de Bain Capital que se unió a la junta tras la inversión de 750 millones de dólares en septiembre de 2020, ha renunciado. Max de Groen, otro socio de Bain Capital, continuará en la junta de Nutanix. Bain Capital sigue siendo un accionista importante de la compañía.
Nutanix (NTNX)는 2025년 5월 15일부터 이사회의 변동 사항을 발표했습니다. 30년 이상의 글로벌 경력을 가진 베테랑 임원 Eric K. Brandt가 리더십과 재무 전문성을 갖추고 이사회에 합류합니다. Brandt는 2016년까지 Broadcom Corporation의 CFO를 역임했으며 Avanir Pharmaceuticals의 CEO와 Allergan의 CFO 등 임원직을 맡았습니다. 현재 Gen Digital, Lam Research, Option Care Health 등 여러 기업 이사회에서 활동 중입니다.
동시에 2020년 9월 7억 5천만 달러 투자 후 이사회에 합류한 Bain Capital의 파트너 David Humphrey가 사임했습니다. 다른 Bain Capital 파트너인 Max de Groen은 Nutanix 이사회에서 계속 활동할 예정입니다. Bain Capital은 여전히 회사의 주요 주주로 남아 있습니다.
Nutanix (NTNX) a annoncé des changements au sein de son conseil d'administration, effectifs à partir du 15 mai 2025. Eric K. Brandt, un cadre expérimenté avec plus de 30 ans d'expérience internationale, rejoint le conseil en apportant une expertise approfondie en leadership et finance. Brandt a été CFO de Broadcom Corporation jusqu'en 2016 et a occupé des postes de direction, notamment CEO d'Avanir Pharmaceuticals et CFO d'Allergan. Il siège actuellement à plusieurs conseils d'administration, dont Gen Digital, Lam Research et Option Care Health.
Parallèlement, David Humphrey, associé chez Bain Capital, qui avait rejoint le conseil suite à leur investissement de 750 millions de dollars en septembre 2020, a démissionné. Max de Groen, un autre associé de Bain Capital, continuera de siéger au conseil de Nutanix. Bain Capital demeure un actionnaire important de l'entreprise.
Nutanix (NTNX) gab Änderungen im Vorstand bekannt, die ab dem 15. Mai 2025 wirksam werden. Eric K. Brandt, ein erfahrener Manager mit über 30 Jahren globaler Erfahrung, tritt dem Vorstand bei und bringt umfassende Führungskompetenz und Finanzexpertise mit. Brandt war bis 2016 CFO bei Broadcom Corporation und hatte Führungspositionen inne, darunter CEO von Avanir Pharmaceuticals und CFO von Allergan. Derzeit sitzt er in mehreren Unternehmensvorständen, darunter Gen Digital, Lam Research und Option Care Health.
Gleichzeitig hat David Humphrey, Partner bei Bain Capital, der nach deren 750-Millionen-Dollar-Investition im September 2020 in den Vorstand eingetreten war, seinen Rücktritt erklärt. Max de Groen, ein weiterer Partner von Bain Capital, wird weiterhin im Nutanix-Vorstand tätig sein. Bain Capital bleibt ein bedeutender Aktionär des Unternehmens.
- Addition of Eric K. Brandt brings extensive financial and operational expertise from his roles as CFO of Broadcom and CEO of Avanir Pharmaceuticals
- Bain Capital maintains significant stockholder position and board representation through Max de Groen
- Company has shown substantial growth and scaled profits since Bain Capital's $750 million investment in 2020
- Loss of David Humphrey's expertise and perspective from the board of directors
New Board Member Eric K. Brandt Brings Extensive Leadership and Finance Experience to Nutanix Board
David Humphrey Resigns from Nutanix Board
SAN JOSE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Nutanix (NASDAQ: NTNX), a leader in hybrid multicloud computing, announced today that it has added Eric K. Brandt to its board of directors, effective May 15, 2025.
“Eric brings deep expertise in both CEO and CFO roles across a variety of industries. His long-term service on boards of public companies also gives him a richness of experience from which Nutanix is sure to benefit,” said Virginia Gambale, Chair of the Board at Nutanix. “I look forward to serving with him together on the Nutanix board as the company continues to focus on driving sustainable, profitable growth while providing customers with a single platform for running applications and managing data, anywhere.”
Brandt is a seasoned executive and board director with more than 30 years of global experience spanning finance, operations, and corporate governance. He served as Chief Financial Officer of Broadcom Corporation from 2007 until it was acquired by Avago Technologies Limited in 2016, where he played a pivotal role in the company’s growth into one of the world’s largest semiconductor firms. Prior to that, he held senior executive positions, including President and CEO of Avanir Pharmaceuticals, Inc. and Chief Financial Officer of Allergan, Inc. Brandt currently serves on the boards of Gen Digital Inc., Lam Research Corporation, The Macerich Company, and Option Care Health, Inc. He previously served on the boards of Altaba Inc. and DENTSPLY SIRONA Inc., among others. He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Additionally, David Humphrey resigned from Nutanix’s board of directors, effective May 15, 2025. Humphrey, a Partner at Bain Capital, joined the Nutanix Board as part of Bain Capital’s
“We thank David for the constructive engagement, guidance and expertise that he brought to the board during a period of significant transformation and growth for Nutanix,” said Gambale. “We are grateful for his valuable contributions and the investment of service he has made over the past four years.”
“Since Bain Capital’s investment in September 2020, Nutanix has grown substantially, evolved into a hybrid multicloud leader, and scaled its profits and cash flows significantly. We are impressed by the company’s performance and believe it has significant opportunity ahead as well,” said Humphrey. “Bain Capital remains a significant stockholder of Nutanix and continues to value its partnership with Nutanix,” added de Groen. “I look forward to my continued service on the Nutanix Board.”
About Nutanix
Nutanix is a global leader in cloud software, offering organizations a single platform for running applications and managing data, anywhere. With Nutanix, companies can reduce complexity and simplify operations, freeing them to focus on their business outcomes. Building on its legacy as the pioneer of hyperconverged infrastructure, Nutanix is trusted by companies worldwide to power hybrid multicloud environments consistently, simply, and cost-effectively. Learn more at www.nutanix.com or follow us on social media @nutanix.
© 2025 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or unregistered trademarks of Nutanix, Inc. (“Nutanix”) in the United States and other countries. All other brand names or marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release is for informational purposes only and nothing herein constitutes a warranty or other binding commitment by Nutanix. This release contains express and implied forward-looking statements. Such statements are not historical facts and are instead based on Nutanix’s current expectations, estimates and beliefs. The accuracy of such statements involves risks and uncertainties and depends upon future events, including those that may be beyond Nutanix’s control, and actual results may differ materially and adversely from those anticipated or implied by such statements. Any forward-looking statements included herein speak only as of the date hereof and, except as required by law, Nutanix assumes no obligation to update or otherwise revise any of such forward-looking statements to reflect subsequent events or circumstances.
Investor Contact:
Richard Valera
ir@nutanix.com
Media Contact: Jennifer Massaro
pr@nutanix.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6fcb69a5-92eb-43fd-b900-5322ebf501cc
FAQ
Who is Eric K. Brandt and why did Nutanix (NTNX) add him to their board?
Why did David Humphrey resign from Nutanix's (NTNX) board of directors?
What is Eric K. Brandt's current board experience outside of Nutanix (NTNX)?
How has Nutanix (NTNX) performed since Bain Capital's investment in 2020?
